MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) Stock Price & Overview
BIT:1MDGL • US5588681057
Current stock price
The current stock price of 1MDGL.MI is 412.7 EUR. Today 1MDGL.MI is up by 8.78%.
1MDGL.MI Key Statistics
- Market Cap
- 9.372B
- P/E
- N/A
- Fwd P/E
- 465.28
- EPS (TTM)
- -10.87
- Dividend Yield
- N/A
1MDGL.MI Stock Performance
1MDGL.MI Stock Chart
1MDGL.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1MDGL.MI.
1MDGL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1MDGL.MI. The financial health of 1MDGL.MI is average, but there are quite some concerns on its profitability.
1MDGL.MI Earnings
On November 4, 2025 1MDGL.MI reported an EPS of -4.96 and a revenue of 287.27M. The company missed EPS expectations (-133.61% surprise) and beat revenue expectations (13.88% surprise).
1MDGL.MI Forecast & Estimates
24 analysts have analysed 1MDGL.MI and the average price target is 557.23 EUR. This implies a price increase of 35.02% is expected in the next year compared to the current price of 412.7.
For the next year, analysts expect an EPS growth of 50.49% and a revenue growth 443.67% for 1MDGL.MI
1MDGL.MI Groups
Sector & Classification
1MDGL.MI Financial Highlights
Over the last trailing twelve months 1MDGL.MI reported a non-GAAP Earnings per Share(EPS) of -10.87. The EPS increased by 48.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.22% | ||
| ROE | -46.21% | ||
| Debt/Equity | 0.54 |
1MDGL.MI Ownership
1MDGL.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 28.81 | 41.518B | ||
| ARGX | ARGENX SE | 29.23 | 41.431B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.62B | ||
| 2X1 | ABIVAX SA | N/A | 7.62B | ||
| ABVX | ABIVAX SA | N/A | 7.612B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| GLPG | GALAPAGOS NV | N/A | 1.605B | ||
| NANO | NANOBIOTIX | N/A | 1.361B | ||
| PHGN | PHARMING GROUP NV | 47.2 | 1.009B | ||
| PHARM | PHARMING GROUP NV | 47.1 | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 946.39M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M | ||
| IVA | INVENTIVA SA | N/A | 907.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1MDGL.MI
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Company Info
IPO: 2007-02-06
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Drive, Suite 400
West Conshohocken PENNSYLVANIA US
Employees: 528
Phone: 14043809263
MADRIGAL PHARMACEUTICALS INC / 1MDGL.MI FAQ
What does MADRIGAL PHARMACEUTICALS INC do?
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 528 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Can you provide the latest stock price for MADRIGAL PHARMACEUTICALS INC?
The current stock price of 1MDGL.MI is 412.7 EUR. The price increased by 8.78% in the last trading session.
Does MADRIGAL PHARMACEUTICALS INC pay dividends?
1MDGL.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1MDGL stock?
1MDGL.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for MADRIGAL PHARMACEUTICALS INC?
The Revenue of MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) is expected to grow by 443.67% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for 1MDGL stock?
MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) currently has 528 employees.
Can you provide the upcoming earnings date for MADRIGAL PHARMACEUTICALS INC?
MADRIGAL PHARMACEUTICALS INC (1MDGL.MI) will report earnings on 2026-02-19, before the market open.